DuPont de Nemours, Inc. (DD) Analyst/Investor Day Transcript

DuPont's 2025 Investor Day detailed a strategic transformation post-Electronics spin-off and Aramids divestiture, sharpening its focus on Healthcare & Water Technologies and Diversified Industrials. The company targets a 3-4% organic revenue CAGR, 150-200 basis points of EBITDA margin expansion, and an 8-10% EPS CAGR by 2028, aiming for 25-25.5% EBITDA margins. This outlook is driven by a portfolio aligned with high-growth end markets, enhanced innovation, operational excellence, and disciplined capital allocation, including bolt-on M&A and shareholder returns, with projected EPS growth being incremental to capital deployment.

Analysis

DuPont's 2025 Investor Day outlines a significant strategic transformation, pivoting the company into a more focused, less cyclical multi-industrial firm following the spin-off of its Electronics business and the divestiture of its Aramids unit. The 'New DuPont' will be structured around two segments: Healthcare & Water Technologies (approx. 50% of sales) and Diversified Industrials (approx. 50%). Management has issued a clear medium-term financial framework, targeting a 3-4% organic revenue CAGR, 150-200 basis points of EBITDA margin expansion to a 25-25.5% profile, and an 8-10% EPS CAGR by 2028. Notably, this EPS growth target explicitly excludes the potential upside from deploying excess capital. Growth is expected to be driven by the Healthcare & Water segment, which is projected to grow in the mid-single-digits, benefiting from secular trends and a high recurring revenue base in Water of over 70%. The Diversified Industrials segment is targeted for GDP-level growth, with a primary focus on margin expansion through operational excellence and a new 'business system' championed by new leadership. The capital allocation strategy reinforces this pivot, prioritizing a strong balance sheet (less than 2x net debt/EBITDA), a dividend payout of 35-45%, and the deployment of approximately $1.5 billion in excess cash over three years, plus $1.2 billion in proceeds from the Aramids sale, toward bolt-on M&A in Healthcare & Water and opportunistic share repurchases.

Key Decisions for Investors

• Investors should evaluate the post-spin valuation of 'New DuPont' against its multi-industrial peer set, as management has explicitly signaled a readiness to deploy share buybacks to address any potential valuation disconnect.
• The achievement of the 8-10% EPS CAGR target is contingent on successful execution of the new operational excellence framework; monitor progress on margin improvement within the Diversified Industrials segment and the elimination of stranded costs as key performance indicators.
• Track the performance of the Healthcare and Water segments, particularly in high-growth sub-markets like medical device components and direct lithium extraction (DLE), as these are the primary engines for the company's targeted above-GDP growth and the focus for future bolt-on M&A.
• While the financial targets are based on conservative end-market assumptions for construction and automotive, any sustained weakness beyond current expectations could pressure the 3-4% revenue growth target, representing a key risk to monitor.